Feb 23, 2022 / 04:45PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
Great. Thank you. Thank you all for joining us. I'm Patrick Donnelly with Tools Diagnostics Analyst here at Citi. Happy to have Thierry Bernard, the CEO at QIAGEN with us for the next 40 minutes or so. If anyone has questions from the investor side, feel free to e-mail me. I will try to get those in.
But Thierry, again, thanks for being here. Maybe to start, you put up a strong 4Q both COVID and non-COVID. Maybe talk through that a bit and again, maybe with a focus on the base business, obviously, we'll get to COVID, I'm sure. Maybe just talk about the recent trends, outlook for this year and then we can dive into some more focused Q&A.
Thierry Bernard - QIAGEN N.V. - CEO, MD & Member of Management Board
Thank you, Patrick, and thanks for having us. I think Q4 of 2021, like 2021 full year, I think, is the concrete translation of what we have been saying for some months now, and when it's not just a marketing slogan. But we do believe that we are COVID-relevant but not
Qiagen NV at Citi Healthcare Conference (Virtual) Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers